Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3755-3760

  Fricker, S P ^a,b   Buckley, R G ^a  

^a JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^b GENZYME CORPORATION   (United States)

Author keywords

Antitumour agents; Cytotoxicity assay; Human tumour cells; MTT; Sulforhodamine B

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; RHODAMINE B;

ARTICLE; CELL COUNT; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; PRIORITY JOURNAL; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; CISPLATIN; COLORIMETRY; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; MITOMYCIN; RHODAMINES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 0030514288     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Goldin A, Schepartz SA, Venditti JM and Devita VT: Historical development and current strategy of the National Cancer Institute drug development programme. In: Methods in Cancer Research, (Devita Jr V.T. and Busch, H., eds). Academic Press Inc. New York, 1974, pp165-245.
2. Corhett TH, Valeriote FA and Baker LH: Is the P388 murine tumour no longer adequate as a drug discovery model. Invest New Drugs 5: 3-20, 1987.
3. Venditti JM, Wesley RA and Plowman J: Current NCl preelinical antitumour screening in vivo: results of tumour panel screening 1976-1982 and future directions. In: Advances in Pharmacology and Chemotherapy, (Garrattini, S., Goldin, A. and Hawking, F., eds) Academic Press Inc., Orlando FL, 1984, ppl-20.
4. Chabner BA: In defense of cell line screening. J Natl Cancer Inst 82: 1083-1085, 1990.
5. Schwartsmann G and Workman P: Anticancer drug screening and discovery in the 1990s: A European perspective. Eur J Cancer 29A: 3-14, 1993.
6. Francis GE: Theoretical and practical considerations in screening strategies for differentiation agents. Differentiation 57: 63-75, 1994.
7. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbot BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumour cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
8. Hills CA, Kelland LR, Abel O, Siracky J, Wilson AP and Harrap KR: Biological properties of ten human ovarian carcinoma lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-534, 1989.
9. Fricker SP and Buekley RG: Characterisation of a human tumour cell line panel for screening of anti-tumour agents in vitro. Biochem Soc Trans 17: 1049-1050, 1989.
10. Hill BT, Whelan RDH and Hosking LK: Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening. Invest New Drugs 6: 11-18, 1988.
11. Fricker SP: The application of Sulforhodamine B as a colorimetric endpoint in a cytoloxicity assay. Toxicol. In Vitro 8: 821-822, 1994.
12. Skehan P, Storeng R, Scudiero D, Monks DA, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anti-cancer drug creening. J Natl Cancer Inst 82: 1107-1112, 1990.
13. Mossman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63, 1983.
14. Leibovitz A, Stinson JC, McCombs III WB, McCoy CE, Mazur KC and Mabry ND: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569, 1976.
15. Fogh J and Trempe G: New human cell lines. Human tumour cells in vitro, ed Fogh J, Plenum Press, New York, pp 115-154, 1975.
16. Engel, L.W., Young, N.A., Tralka, T.S., Lippman, M.E., O'Brien, S.J. and Joyce, M.J. (1978) Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res., 38, 3352-3364.
17. Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA and Arnstein P: Human bladder carcinoma: Characterization of two new tumour cell lines and search for tumour viruses. J Natl Cancer Inst 58: 881-890, 1977.
18. Fogh J, Wright WC and Loveless JD: Absence of HeLa cell contamination in 169 cell lines derived from human tumours. J Natl Cancer Inst 58: 209-214, 1977.
19. Higgins JD III, Neely L and Fricker S: Synthesis and cytotoxicity of some cyclometallated palladium complexes. J Inorganic Biochemistry 49: 149-156, 1993.
20. Fricker SP: Screening for new metal anti-tumour agents. Metal Ions in Biology and Medicine, eds P Collery, LA Poirier, M Manfait, J-C Etienne, John Libbey Eurotext, Paris 452-456, 1990.
21. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Mclnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM and Von Hoff DD: Application of a human tumour colony-forming assay to new drug screening. Cancer Res 45: 2145-2153, 1985.
22. Roper PR and Drewinko B: Comparison of in vitro methods to determine drug induced lethality. Cancer Res 36: 2182-2188, 1976.
23. Borenfreund E, Babich H and Martin-Alguacil N: Comparison of two in vitro cytotoxicity tests - the neutral red (NR) and tetrazolium MTT tests. Toxic in Vitro 2: 1-6, 1988.
24. Borenfreund E, Babich H and Martin-Alguacil N: Rapid chemosensitivity assay with human normal and tumour cells in vitro. In Vitro Cell Dev Biol 26: 1030-1034, 1990.
25. Rubenstein LV, Shoemaker RH, Paull KD, Simon MR, Tosini S, Skehan P, Scudiero DA, Monks MA and Boyd MR: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium versus a protein assay against a diverse panel of human tumour cell lines. J Natl Cancer Inst 82: 1113-1118, 1990